Gynecologic Cytology Guidelines
European guidelines for quality assurance in cervical cancer screening: recommendations for cervical cytology terminology,(Cytopathology 2007, 18, 213–219)
The European guidelines for quality assurance in cervical cancer screening "...provides a framework that will allow different terminologies and languages to be translated into standard terminology based on the Bethesda system (TBS) for cytology while retaining the cervical intraepithelial neoplasia (CIN) classification for histology. This approach has followed extensive consultation with representatives of many countries and professional groups as well as a discussion forum published in Cytopathology (2005;16:113).
Jordan, J., Arbyn, M., Martin-Hirsch?, P., Schenck, U., Baldauf, J.-J., Da Silva, D., Anttila, A., Nieminen, P. and Prendiville, W. (2008), European guidelines for quality assurance in cervical cancer screening: recommendations for clinical management of abnormal cervical cytology, part 1. Cytopathology, 19: 342–354. doi:10.1111/j.1365-2303.2008.00623.x
Classification of Munich (II), modified by Soost in 1989 5.
|II||Regenerative cells, immature metaplastic cells, important degenerative or inflammatory changes, para- and hyperkeratinizing cells. Normal endometrial cells even after the menopause.||cytological control if necessary (with or without anti-inflammatory or hormonal treatment)|
|III||Important degenerative, iatrogenic or inflammatory changes of the cells where benignity or malignancy cannot be diagnosed with certainty even if the smear is adequately prepared.||short-term cytological control if necessary after anti-inflammatory or hormonal treatment, or immediate histological control|
|IIID||Mild to moderate dysplasia (CIN I and II)||cytological control in 3 months|
|IIIG||Abnormal cells of the glandular epithelium whose carcinomatous nature cannot be excluded with certainty; if possible with an indication of the endometrial, endocervical or extra-uterine origin of the cells.||cytological or histological control|
|IVa||Severe dysplasia or carcinoma in situ (CIN III)||histological control|
|IVb||Severe dysplasia or carcinoma in situ; invasive carcinoma not excluded||histological control|
|V||Invasive epidermoid carcinoma of the uterine cervix; adenocarcinoma, indicating if possible the endometrial, endocervical or extra-uterine origin of the cells. Other malignant tumours||histological control|
- EUropean Research Organization on Genital Infection and Neoplasia (EUROGIN)
- QUATE (http://zytotraining.schenck.de/admin/user/attachments/Quate-Website.htm)
- QUATE EXAM Form (attached)
- European Federation of Cytology Societies (http://www.cytology-efcs.org)
- France: http://qhc.bmjjournals.com/cgi/content/full/10/2/111
- National Guidelines for Cancer Screening (see attached).
- Canadian Society of Cytology Guidelines for Practice and Quality Assurance in Cytopathology
- NHS Guidelines for Cervical Cancer Screening- second edition
Contributors to this page: admin
Page last modified on Sunday 22 of April, 2012 09:41:33 MDT by admin.
The content on this page is licensed under the terms of the Creative Commons Attribution-ShareAlike License.
- wiki page:
- wiki page:
- file gallery:
- review for next release
- 2009 ASCCP HPV Algorithm
- Needs Review
- Status Tags
- Welcome Authors
- Brief Overview
- 2006 ASCCP Guidelines
- CytologyQACompendium Non-USA
- CytologyQACompendium USA
- Collaboration Model
- GNU Free Documentation License
- Examples (Templates)
- Publication Status
- Formatting Standards